Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.09. | Jones Trading initiates coverage on Bicara stock with Buy rating | 1 | Investing.com | ||
22.08. | H.C. Wainwright senkt Kursziel für Bicara Therapeutics wegen höherer Ausgaben auf 40 US-Dollar | 1 | Investing.com Deutsch | ||
19.08. | Piper Sandler initiates Bicara Therapeutics stock with Overweight rating | 2 | Investing.com | ||
12.08. | Bicara Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
12.08. | Bicara Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.08. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 1.216 | GlobeNewswire (Europe) | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
11.06. | Relay Therapeutics beruft Bicara-CEO in den Vorstand vor Brustkrebsstudie | 17 | Investing.com Deutsch | ||
09.06. | Stifel behält Kaufempfehlung und Kursziel von 48 US-Dollar für Bicara Therapeutics bei | 7 | Investing.com Deutsch | ||
09.06. | Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock | 1 | Investing.com | ||
06.06. | Bicara Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
03.06. | Cantor Fitzgerald maintains overweight rating on Bicara stock | 2 | Investing.com | ||
02.06. | 'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race | 1 | FierceBiotech | ||
02.06. | Stifel bekräftigt Kaufempfehlung für Bicara Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
02.06. | Stifel reiterates Buy rating on Bicara Therapeutics stock | 1 | Investing.com | ||
02.06. | Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock | - | Investing.com | ||
01.06. | ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset | 1 | FierceBiotech | ||
01.06. | Bicara Therapeutics Inc.: Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 | 211 | GlobeNewswire (Europe) | Median DOR of 21.7 months with 80% of responders achieving a deep response (=80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46%... ► Artikel lesen | |
24.05. | Stifel maintains Bicara stock Buy rating, $48 target post-ASCO | 1 | Investing.com | ||
23.05. | Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? | 2 | Benzinga.com | ||
23.05. | Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics | 2 | Investor's Business Daily |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 37,645 | -2,03 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
DYNE THERAPEUTICS | 12,580 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
MBX BIOSCIENCES | 17,330 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering | CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide... ► Artikel lesen | |
89BIO | 14,700 | 0,00 % | Roche To Buy 89bio For Up To $3.5 Billion | ||
BEAM THERAPEUTICS | 23,090 | -2,12 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
APOGEE THERAPEUTICS | 37,520 | -2,34 % | Apogee Therapeutics stock initiated at Outperform by RBC Capital | ||
MINERALYS THERAPEUTICS | 38,510 | -1,10 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
HARMONY BIOSCIENCES | 27,040 | 0,00 % | Deep Dive Into Harmony Biosciences Holdings Stock: Analyst Perspectives (6 Ratings) | ||
MOONLAKE IMMUNOTHERAPEUTICS | 56,38 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
EVOTEC | 6,038 | -3,05 % | Puma Aktie: Neue Gerüchte - Aumovio, Circus, Evotec, Krones und Novo Nordisk im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SCISPARC | 6,130 | 0,00 % | SciSparc Ltd. - 6-K, Report of foreign issuer | ||
PEPGEN | 5,825 | 0,00 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
COGENT BIOSCIENCES | 13,290 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
ARVINAS | 7,750 | 0,00 % | Arvinas stock downgraded by BofA as Pfizer partnership shifts | ||
IMMUNEERING | 8,000 | 0,00 % | Mizuho bestätigt Outperform-Rating für Immuneering nach positiven Studiendaten |